Jan. 13, 2025 — Girolline, a compound extracted from the sea sponge Pseudaxinyssa cantharella, has been investigated for possible antitumor effects and also found to ...

The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities ...

The CRISPR-led gene-editing revolution is set to begin next month in its first ever trial in humans. The small phase 1 trial, to take place in China, will be investigating the method’s safety ...

Out of the many challenges scientists face in bringing genomic medicine to patients, delivery is near the top of the list. Due to these barriers in getting the genetic payload to the correct ...

The Carr Center for Human Rights Policy serves as the hub of the Harvard Kennedy School’s research, teaching, and training in the human rights domain. The center embraces a dual mission: to educate ...

3.5.1 also fixes some issues with and expands 3.5.0's TypeScript definitions.

The one application that has made it famous is the modification of the human genome, which brings the promise of using CRISPR to cure diseases. Since 2012, a lot has happened and drug candidates have ...

TIGIT (T-cell immunoreceptor with Ig and ITIM domains) has emerged as a promising target in cancer immunotherapy due to its critical role in suppressing T-cell-mediated anti-tumor immune responses.

claiming a “massive” human rights violation is happening over a new land expropriation law ...